Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00896727 · ClinicalTrials.gov registry record

S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313

A clinical trial, sponsored by SWOG Cancer Research Network.

Completed
Registry status
2,100
Enrollment target

NCT00896727 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 2,100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00896727 has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
2,100 participants
Enrollment target

Study Summary

RATIONALE: Studying the proteins expressed in tumor tissue samples in the laboratory from patients with cancer may help doctors learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at protein expression in predicting response to treatment using tumor tissue samples from women with stage I, stage II, or stage IIIA breast cancer treated on clinical trial SWOG-9313.

Interventions

  • GENETIC gene expression analysis
  • GENETIC protein expression analysis
  • OTHER laboratory biomarker analysis
  • OTHER fluorescent antibody technique

Trial Details

FieldValue
Enrollment Target 2,100 participants
Start Date 2006-07-17
Est. Completion 2009-04-02

Sponsor

SWOG Cancer Research Network

270 total trials

What the Registry Record Tells You About NCT00896727

The ClinicalTrials.gov registry entry for NCT00896727 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which gene expression analysis is the first listed.

NCT00896727 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00896727 about?

NCT00896727 is a clinical study titled "S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313". RATIONALE: Studying the proteins expressed in tumor tissue samples in the laboratory from patients with cancer may help doctors learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at protein exp...

What is the current status of trial NCT00896727?

This trial is currently completed. The enrollment target is 2,100 participants. The study started on 2006-07-17. Estimated completion is 2009-04-02.

What interventions are being tested in trial NCT00896727?

The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), fluorescent antibody technique (OTHER).

Who is sponsoring clinical trial NCT00896727?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.